Cell & Gene
Driving Innovation in Cell & Gene Therapy Manufacturing
Cell and gene therapies represent a revolutionary shift in medicine, transforming lives with groundbreaking treatments for previously untreatable conditions. However, scaling these therapies for widespread patient access requires overcoming critical manufacturing challenges.
Manufacturing challenges, automation solutions
Most cell and gene therapies originate in academic settings designed for research, not commercial-scale production. Contamination risks, process inconsistencies, and the complexity of aseptic manufacturing demand a shift to advanced automation solutions.
At 3P innovation, we bring extensive experience in pharmaceutical automation to support the scale-up of these transformative treatments.
These therapies are costly, often exceeding £1 million per dose. Reducing costs while ensuring quality demands automation - not just for efficiency but to address the shortage of skilled aseptic technicians. Through automation, we empower manufacturers to scale production, reduce labour dependencies, and maintain compliance with stringent global regulations.
Our cryoFIL® cryovial filling platform is built to meet the unique demands of cell and gene therapy fill-finish processing. By designing compact, high-performance systems that integrate feedback sensors for precise quality control, we help manufacturers navigate technical and regulatory complexities seamlessly.
